Zentalis Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing small-molecule treatments for cancer, Zentalis focuses on targeted therapies for solid tumors. Its lead drug candidate, azenosertib (ZN-c3), is a WEE1 inhibitor designed to block a protein that helps cancer cells repair damaged DNA. The company is headquartered in San Diego, California.
Granted 57.1K
Granted 57.1K
Granted 57.1K
Granted 57.1K
Granted 57.1K
Granted 114.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Myers Scott DunsethDirector · 1 transaction | +16.9% | 395.9K | 57.1K | — | — |
| Johnson David MichaelDirector · 1 transaction | +22.8% | 307.5K | 57.1K | — | — |
| Skvarka JanDirector · 1 transaction | +27.6% | 264.3K | 57.1K | — | — |
| Walker Luke NathanielDirector · 1 transaction | +39.6% | 201.4K | 57.1K | — | — |
| Kariuki EnochDirector · 1 transaction | +41.6% | 194.5K | 57.1K | — | — |
| Campbell ShannonDirector · 1 transaction | — | 114.2K | 114.2K | — | — |
Select a row to see that insider’s individual transactions.